...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >Acceptability of bone antiresorptive therapy among HIV-infected adults at different stages of antiretroviral therapy
【24h】

Acceptability of bone antiresorptive therapy among HIV-infected adults at different stages of antiretroviral therapy

机译：抗逆转录病毒治疗不同阶段的艾滋病毒感染成年人骨反射治疗的可接受性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: Both HIV infection and antiretroviral therapy (ART) are associated with -significant decreases in bone mineral density (BMD) and increased fracture rates. To prepare for a randomized controlled trial of prophylactic bone antiresorptive therapy during ART initiation, we assessed the acceptability of this strategy, bone health knowledge, and fracture risk among HIV-infected adults.Methods: HIV-infected adults with no history of osteoporosis were recruited from one tertiary and one primary care HIV clinic. Participants completed a questionnaire and underwent chart review. The primary outcome was the proportion of respondents expressing interest in taking prophylactic bone antiresorptive therapy in conjunction with ART.Results: Of 112?respondents, 25.0% were ART na?ve, 23.2% had been taking ART for?≤1?year, and 51.8% had been taking ART for >1?year. Half (51.9%) indicated interest in taking short-course prophylactic bone antiresorptive therapy; this did not differ by ART status (53.6% among ART-na?ve, 51.3% among ART-treated; P=0.84, chi-square test). In exploratory multivariable analysis adjusted for ART status, a greater number of pills taken per day was positively associated with this outcome (adjusted odds ratio [OR] =1.12?per pill, 95% confidence limit [CL]?=1.01, 1.25), while male sex was inversely associated (adjusted OR =0.05, 95% CL?=0.01, 0.24). Among those willing to take therapy, most (80.4%) were willing to do so for “as long as needed” and preferred weekly dosing (70.9%) to daily dosing (12.7%).Conclusions: Half of this sample would be willing to take bone antiresorptive therapy together with ART, with preferences for weekly dosing and for whatever duration may be required. These data will inform the design of future trials to protect bone health in HIV.
机译：目的：艾滋病毒感染和抗逆转录病毒治疗（ART）与骨矿物密度（BMD）的显着降低相关，并增加骨折率。为准备在艺术启动期间预防性骨抗血糖治疗的随机对照试验，我们评估了艾滋病毒感染的成年人中这种策略，骨骼健康知识和骨折风险的可接受性。招募艾滋病毒感染的成年人，没有骨质疏松症的历史从一个三级和一个初级保健艾滋病毒诊所。参与者完成了调查问卷并进行了图表审查。主要结果是表达对艺术的预防性骨反射治疗的患者的患者的比例。结果：112个？受访者，25.0％是艺术Na've，23.2％曾经为艺术作用？≤1？一年，和51.8％一直在艺术> 1？一年。一半（51.9％）表示兴趣采取短期预防性骨骨反射治疗;这与艺术状况没有差异（Art-Na've的53.6％，艺术处理的51.3％; P = 0.84，Chi-Square测试）。在用于艺术状态调整的探索性多变量分析中，每天服用更多数量的药丸与此结果正相关（调整后的差距[或] = 1.12？每丸，95％的置信限[CL]？= 1.01,1.25），虽然男性对逆转相关（调整或= 0.05,95％Cl？= 0.01,0.24）。在那些愿意服用治疗的人中，大多数（80.4％）愿意为“只需要”，并优于每周给药（70.9％）到每日给药（12.7％）。结论：这个样本的一半会愿意将骨骼反射疗法与艺术一起服用，优先于每周给药，并且无论可能需要持续时间。这些数据将向未来的试验设计通知艾滋病病毒治疗骨骼健康。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号